Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Group B Streptococcus (GBS) capsular polysaccharides (CPS) are high molecular weight carbohydrate polymers that form a capsule surrounding the bacterial cell. This capsule is a major virulence factor, enabling GBS to evade host immune defenses, particularly by inhibiting phagocytosis. The CPS defines the serotype of GBS and is essential for its pathogenicity. There are at least ten known GBS capsular serotypes: Ia, Ib, II, III, IV, V, VI, VII, VIII, and IX. The capsule’s primary function is to prevent opsonophagocytosis by masking underlying bacterial antigens from immune detection. Protective antibodies target specific epitopes within these polysaccharides—especially those containing sialic acid—which has driven development of conjugate vaccines using purified or synthetic versions of these structures.
Antibodies targeting CPS promote opsonization and phagocytosis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Group B Streptococcus Capsular Polysaccharides (None).